Shasun Chemicals and Drugs Limited, Suven Pharmaceuticals Limited and Innovasynth Technologies (India) Limited have formed a research, development and manufacturing alliance to service the needs of the global life science companies in collaboration with Austin Chemical Company of USA. The alliance would focus on offering drug development services from discovery through distribution. The members would work towards leveraging on individual core competence and share resources to provide the life science industry a comprehensive platform of services.
The members of the alliances are in the process of developing systems that would help integrate personnel, capacities and capabilities to offer a wide range of products and services to include, FTE's in the discovery and early stage development, discovery support services, development of new NCE's for clinical studies, conduct pre-clinical and clinical trials in India, offer late stage product development and manufacturing to include formulation development, ultimately offer commercial product manufacture, supply and distribution. All the above services would be supported by global regulatory compliance.
The alliance as it develops would help rationalize capital investment, share resources among members without breach of Intellectual property and retain individual identity. The members of the alliance would work together to develop uniform quality systems, technical and project management teams to facilitate comprehensive services.
Dr. Don Butler, Chief Scientific Officer, Austin Chemical, a renowned scientist with over 4 decades of discovery and development experience along with other industry experts would work with the chemists in the alliance to develop innovative chemistry and processes.
The alliance would focus on promoting these services to the global life science companies to help them better transition their drug development outsourcing within India. The alliance would also focus on technology based small pharma and biopharma companies in Europe and US to help them accelerate their drug development via cost effective services.
The alliance is seen as the first step towards integrating services that would help bring speed, quality and value as well as recognition to the networking capabilities of Indian Pharmaceutical companies as we prepare for an era of Intellectual Property compliance post 2005.